Advertisement
BIIB vs EMBC
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Buy and EMBC is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 0 FA rating(s) are green whileEMBC’s FA Score has 2 green FA rating(s).
- BIIB’s FA Score: 0 green, 5 red.
- EMBC’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 6 TA indicator(s) are bullish while EMBC’s TA Score has 5 bullish TA indicator(s).
- BIIB’s TA Score: 6 bullish, 3 bearish.
- EMBC’s TA Score: 5 bullish, 3 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +0.67% price change this week, while EMBC (@Medical Specialties) price change was -1.32% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.37%. For the same industry, the average monthly price growth was +3.14%, and the average quarterly price growth was +9.05%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +7.08%. For the same industry, the average monthly price growth was +2.38%, and the average quarterly price growth was +1.09%.
Reported Earning Dates
BIIB is expected to report earnings on Jul 23, 2025.
EMBC is expected to report earnings on Aug 07, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (+0.37% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Medical Specialties (+7.08% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BIIB | EMBC | BIIB / EMBC | |
| Capitalization | 31.3B | 764M | 4,097% |
| EBITDA | 2.04B | 208M | 980% |
| Gain YTD | -17.872 | -51.903 | 34% |
| P/E Ratio | 26.95 | 13.65 | 198% |
| Revenue | 9.84B | 1.12B | 877% |
| Total Cash | 1.05B | 299M | 351% |
| Total Debt | 7.34B | 1.64B | 448% |
BIIB | ||
|---|---|---|
OUTLOOK RATING 1..100 | 67 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 71 | |
PRICE GROWTH RATING 1..100 | 64 | |
P/E GROWTH RATING 1..100 | 97 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BIIB | EMBC | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 47% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 70% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 55% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 70% | 2 days ago 85% |
| Advances ODDS (%) | 7 days ago 54% | 2 days ago 75% |
| Declines ODDS (%) | 2 days ago 70% | 6 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 62% | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 38% | 2 days ago 84% |
Advertisement
BIIB and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | -0.39% | ||
| AMGN - BIIB | 54% Loosely correlated | +0.75% | ||
| PFE - BIIB | 49% Loosely correlated | +0.21% | ||
| SNY - BIIB | 45% Loosely correlated | +0.96% | ||
| NVS - BIIB | 44% Loosely correlated | +0.83% | ||
| GILD - BIIB | 43% Loosely correlated | +0.18% | ||
More | ||||
EMBC and
Correlation & Price change
A.I.dvisor indicates that over the last year, EMBC has been loosely correlated with AZTA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if EMBC jumps, then AZTA could also see price increases.
| Ticker / NAME | Correlation To EMBC | 1D Price Change % | ||
|---|---|---|---|---|
| EMBC | 100% | +0.52% | ||
| AZTA - EMBC | 37% Loosely correlated | +0.62% | ||
| IRMD - EMBC | 37% Loosely correlated | -1.73% | ||
| WAT - EMBC | 36% Loosely correlated | -0.96% | ||
| MTD - EMBC | 35% Loosely correlated | -0.83% | ||
| IQV - EMBC | 35% Loosely correlated | +0.08% | ||
More | ||||